| 204.8 4.33 (2.16%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 242.12 | 1-year : | 282.8 |
| Resists | First : | 207.3 | Second : | 242.12 |
| Pivot price | 200.91 |
|||
| Supports | First : | 191.9 | Second : | 182.38 |
| MAs | MA(5) : | 202.62 |
MA(20) : | 196.88 |
| MA(100) : | 190.16 |
MA(250) : | 166.39 |
|
| MACD | MACD : | 2.6 |
Signal : | 2.1 |
| %K %D | K(14,3) : | 78.1  |
D(3) : | 79.2 |
| RSI | RSI(14): 60.1 |
|||
| 52-week | High : | 210.51 | Low : | 130.05 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AZN ] has closed below upper band by 28.2%. Bollinger Bands are 1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 205.7 - 206.86 | 206.86 - 207.91 |
| Low: | 199.47 - 200.99 | 200.99 - 202.39 |
| Close: | 202.59 - 204.8 | 204.8 - 206.82 |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Sat, 18 Apr 2026
AstraZeneca’s Danicopan Korea Study: Real-World Data That Could Shape AZN’s Rare Disease Edge - TipRanks
Sat, 18 Apr 2026
AstraZeneca PLC - depositary receipt (AZN) price target increased by 107.33% to 202.76 - MSN
Fri, 17 Apr 2026
AZN Stock Quote Price and Forecast - CNN
Thu, 16 Apr 2026
AstraZeneca (AZN) Sees Leadership Changes in CDC Announced by Pr - GuruFocus
Thu, 16 Apr 2026
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock - Eastern Progress
Wed, 15 Apr 2026
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 1,550 (M) |
| Shares Float | 1,540 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 56.7 (%) |
| Shares Short | 1,980 (K) |
| Shares Short P.Month | 2,490 (K) |
| EPS | 6.53 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 31.37 |
| Profit Margin | 17.4 % |
| Operating Margin | 21.5 % |
| Return on Assets (ttm) | 8.1 % |
| Return on Equity (ttm) | 22.8 % |
| Qtrly Rev. Growth | 4 % |
| Gross Profit (p.s.) | 30.96 |
| Sales Per Share | 37.89 |
| EBITDA (p.s.) | 12.43 |
| Qtrly Earnings Growth | 53.9 % |
| Operating Cash Flow | 14,570 (M) |
| Levered Free Cash Flow | 7,870 (M) |
| PE Ratio | 31.31 |
| PEG Ratio | 0 |
| Price to Book value | 6.52 |
| Price to Sales | 5.4 |
| Price to Cash Flow | 21.78 |
| Dividend | 2.15 |
| Forward Dividend | 0 |
| Dividend Yield | 1% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|